🟢 Quantum BioPharma is trading 6.25% up today after FDA clearance for Phase 2 Lucid-MS trial

Quantum BioPharma is trading 6.25% up at $3.40 after renewed attention to its September 11 FDA-clearance announcement for a Phase 2 Lucid-MS trial in multiple sclerosis.

• The treatment is designed to protect and potentially repair myelin, representing a first-in-class mechanism.
• FDA clearance and the planned randomized, placebo-controlled trial have attracted positive analyst attention.
• Major U.S. indexes are lower at midday, suggesting company-specific biotech enthusiasm is outweighing broader risk-off sentiment; no newer September 14 company announcement was identified.